Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions.

[1]  P. Libby,et al.  Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure , 2019, Circulation.

[2]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[3]  N. Câmara,et al.  Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? , 2018, The FEBS journal.

[4]  Dave L Dixon,et al.  Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) , 2017, Circulation. Heart failure.

[5]  Song Jiang,et al.  TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses , 2017, The Journal of Immunology.

[6]  T. E. Schultz,et al.  The RP105/MD‐1 complex: molecular signaling mechanisms and pathophysiological implications , 2017, Journal of leukocyte biology.

[7]  C. Garlanda,et al.  Expression and function of IL-1R8 (TIR8/SIGIRR): a regulatory member of the IL-1 receptor family in platelets. , 2016, Cardiovascular research.

[8]  I. Manabe,et al.  Macrophages in age-related chronic inflammatory diseases , 2016, npj Aging and Mechanisms of Disease.

[9]  S. Epelman,et al.  Chronic Heart Failure and Inflammation: What Do We Really Know? , 2016, Circulation research.

[10]  C. Garlanda,et al.  Regulatory Role of IL-1R8 in Immunity and Disease , 2016, Front. Immunol..

[11]  Song Jiang,et al.  TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling , 2016, The Journal of Immunology.

[12]  G. Schmitz,et al.  Epicardial adipocyte hypertrophy: Association with M1-polarization and toll-like receptor pathways in coronary artery disease patients. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[13]  L. Pączek,et al.  Inflammatory Markers Change with Age, but do not Fall Beyond Reported Normal Ranges , 2015, Archivum Immunologiae et Therapiae Experimentalis.

[14]  Taura L. Barr,et al.  Systemic Transcriptional Alterations of Innate and Adaptive Immune Signaling Pathways in Atherosclerosis, Ischemia Stroke, and Myocardial Infarction , 2015, Journal of bioanalysis & biomedicine.

[15]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.

[16]  G. Vilahur,et al.  Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor , 2014, Front. Physiol..

[17]  Gregory M. Fomovsky,et al.  Transcriptional reversion of cardiac myocyte fate during mammalian cardiac regeneration. , 2014, Circulation research.

[18]  D. Mann,et al.  Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart , 2014, Proceedings of the National Academy of Sciences.

[19]  Jin Wei,et al.  Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. , 2014, Biochemical and biophysical research communications.

[20]  I. Manabe,et al.  Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. , 2014, Journal of atherosclerosis and thrombosis.

[21]  J. Cleveland,et al.  Human Myocardium Releases Heat Shock Protein 27 (HSP27) after Global Ischemia: The Proinflammatory Effect of Extracellular HSP27 through Toll-like Receptor (TLR)-2 and TLR4 , 2014, Molecular medicine.

[22]  Xin Guo,et al.  Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes. , 2013, Cardiovascular research.

[23]  D. Sudan,et al.  Upregulation of IL-1&bgr;, IL-6, and CCL-2 by a Novel Mouse Model of Pancreatic Ischemia-Reperfusion Injury , 2013, Transplantation.

[24]  L. Palmqvist,et al.  Reduced expression of NLRP3 and MEFV in human ischemic heart tissue. , 2013, Biochemical and biophysical research communications.

[25]  N. Voelkel,et al.  The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse , 2011, Proceedings of the National Academy of Sciences.

[26]  D. Mann,et al.  Therapeutic targeting of innate immunity in the failing heart. , 2011, Journal of molecular and cellular cardiology.

[27]  Yan Li,et al.  Myocardial Ischemia Activates an Injurious Innate Immune Signaling via Cardiac Heat Shock Protein 60 and Toll-like Receptor 4* , 2011, The Journal of Biological Chemistry.

[28]  M. Scherrer-Crosbie,et al.  Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. , 2008, American journal of physiology. Heart and circulatory physiology.

[29]  C. Tschöpe,et al.  Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice1 , 2008, The Journal of Immunology.

[30]  S. Paik,et al.  Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide , 2007, Cell.

[31]  A. Knowlton,et al.  HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. , 2007, American journal of physiology. Heart and circulatory physiology.

[32]  B. Rollins,et al.  Critical Role of Monocyte Chemoattractant Protein-1/CC Chemokine Ligand 2 in the Pathogenesis of Ischemic Cardiomyopathy , 2007, Circulation.

[33]  S. Slørdahl,et al.  Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction , 2005, Heart.

[34]  L. Kuller,et al.  The Chronic Inflammatory Hypothesis for the Morbidity Associated with Morbid Obesity: Implications and Effects of Weight Loss , 2004, Obesity surgery.

[35]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[36]  A. Khaghani,et al.  Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  D. Mann,et al.  Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes , 2004, Circulation.

[38]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[39]  S. Anker,et al.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.

[40]  Ruslan Medzhitov,et al.  Toll-like receptors and innate immunity , 2001, Nature Reviews Immunology.

[41]  Y. Mándi,et al.  Cytokine Production and Antibodies against Heat Shock Protein 60 in Cardiomyopathies of Different Origins , 2000, Pathobiology.

[42]  D. Mann,et al.  Innate immunity in the adult mammalian heart: for whom the cell tolls. , 2010, Transactions of the American Clinical and Climatological Association.

[43]  W. Chao.  Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. , 2009, American journal of physiology. Heart and circulatory physiology.